GAVRETO (pralsetinib)

pralsetinib · Blueprint Medicines; Genentech (Roche)

Drug timelines are a Plus or Pro feature.

1 regulatory and trial event tracked for GAVRETO (pralsetinib), covering 2026-03-05 to 2026-03-05. Get the full timeline:

Most recent: Clinical Trial Update: A Study of Pralsetinib Versus Standard of Care for First-Line Treatment of Advanced Non-Small Cell Lung Cancer (NSCLC) [Phase 3]

See pricing